Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA comprehensive review suggests that weight loss medications, specifically GLP-1 drugs like Wegovy and Mounjaro, could offer a promising treatment for individuals with binge eating disorder. The research, led by University College London, analysed data from 25 trials involving over 8,000 participants, revealing moderate reductions in binge eating and related behaviours such as emotional eating. Experts caution that the current evidence is limited, with many studies having a high risk of bias, and stress the need for further large-scale, high-quality clinical trials to confirm these findings. It is suggested that these medications may prove most effective as part of a broader treatment approach, combining pharmacological and psychological care, rather than as a standalone solution. Binge eating disorder affects approximately 17 million people globally, and charity Beat highlights the complexity of GLP-1s and the importance of thorough mental and physical health checks before their use. In fullWegovy and Mounjaro could be used to treat patients with eating disordersMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Weight loss drugs could offer ‘promising treatment’ for binge eating disorder
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA comprehensive review suggests that weight loss medications, specifically GLP-1 drugs like Wegovy and Mounjaro, could offer a promising treatment for individuals with binge eating disorder. The research, led by University College London, analysed data from 25 trials involving over 8,000 participants, revealing moderate reductions in binge eating and related behaviours such as emotional eating. Experts caution that the current evidence is limited, with many studies having a high risk of bias, and stress the need for further large-scale, high-quality clinical trials to confirm these findings. It is suggested that these medications may prove most effective as part of a broader treatment approach, combining pharmacological and psychological care, rather than as a standalone solution. Binge eating disorder affects approximately 17 million people globally, and charity Beat highlights the complexity of GLP-1s and the importance of thorough mental and physical health checks before their use. In fullWegovy and Mounjaro could be used to treat patients with eating disordersMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
